News from eisai inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

08:00 ET

Lorcaserin Data to be Presented at The Obesity Society's Annual Scientific Meeting

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data for BELVIQ® (lorcaserin HCl) CIV will be presented during...

Oct 28, 2014, 18:20 ET

Eisai and Arena Pharmaceuticals Report Results of an Investigational Pilot Study of Coadministration of Lorcaserin HCl and Phentermine HCl

 Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results of a pilot study to assess the safety of lorcaserin...

Oct 24, 2014, 10:01 ET
http://www.multivu.com/players/English/7353251-eisai-search-for-next-medikidz-star-contest-for-kids-living-with-epilepsy/gallery/image/da225740-911e-4944-8ed3-4d4ce1d90b1a.HR.jpg

Eisai Launches "Search for the Next Medikidz Star" Contest for Kids Living With Epilepsy

Eisai Inc., a leader in the epilepsy community, announces the launch of the "Search for the Next Medikidz Star," a consumer contest to...

Oct 21, 2014, 19:01 ET

Demostradas la eficacia y la seguridad a largo plazo de la monoterapia con Zonegran® (zonisamida) una vez al día en la extensión de un estudio fundamental

COMUNICADO DE PRENSA SOLO PARA MEDIOS DE LA UE: NO PARA LOS MEDIOS SUIZOS/ESTADOUNIDENSES  Zonegran® (zonisamida) continúa...

Oct 21, 2014, 19:01 ET

Offene Verlängerung der Zulassungsstudie zeigt Langzeitsicherheit und Wirksamkeit der Monotherapie mit einmal täglich einzunehmendem Zonegran® (Zonisamid)

Zonegran® (Zonisamid) ist auch in der Langzeit-Monotherapie für die Behandlung fokaler epileptischer Anfälle bei Erwachsenen mit...

Oct 21, 2014, 19:01 ET

Zonegran® (zonisamide) en monotherapie: securite d’emploi et efficacite confirmees en administration unique quotidienne

COMMUNIQUÉ DE PRESSE DESTINÉ AUX MÉDIAS EUROPÉENS UNIQUEMENT : NE CONCERNE PAS LES JOURNALISTES...

Oct 21, 2014, 19:01 ET

Studio di estensione in aperto conferma la sicurezza e l'efficacia a lungo termine di Zonegran® (zonisamide) come monoterapia in monosomministrazione giornaliera

COMUNICATO STAMPA DESTINATO ESCLUSIVAMENTE AI MEDIA DELL'UE: NON DESTINATO AI GIORNALISTI DI SVIZZERA/STATI UNITI  Una nuova pubblicazione...

Oct 20, 2014, 08:30 ET
Eisai logo.

Eisai Announces FDA Acceptance of Supplemental New Drug Application for Antiepileptic Drug Perampanel as Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company's Supplemental New Drug Application...

Oct 14, 2014, 16:05 ET
Eisai logo

FDA Grants Eisai's sNDA for Rufinamide Priority Review as Adjunctive Treatment in Pediatric Patients Ages 1-4 for Seizures Associated with Lennox-Gastaut Syndrome

 Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's sNDA for rufinamide and granted it...

Oct 14, 2014, 16:03 ET

U.S. FDA Grants Eisai's Investigational Agent Lenvatinib Priority Review Designation for the Treatment of Advanced Thyroid Cancer

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its in-house...

Oct 14, 2014, 15:14 ET
http://www.multivu.com/players/English/7342251-eisai-launches-mbc-infocenter-for-women-with-metastatic-breast-cancer/gallery/image/fae38083-4904-4393-a600-1fa87e2227d5.HR.jpg

Eisai Launches New Online Resource Helping Women Living with Metastatic Breast Cancer Navigate Their Journey

Understanding the burden of metastatic breast cancer (MBC), and the toll it takes on patients and their loved ones, Eisai Inc. announced today the...

Oct 13, 2014, 07:55 ET

FDA Approves AKYNZEO® (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)

Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and...

Oct 10, 2014, 11:36 ET
Eisai logo.  (PRNewsFoto/Eisai Inc.)

Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 Clinical Trial Analysis of BELVIQ® (lorcaserin HCl) CIV in Postgraduate Medicine

 Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that a pooled analysis of the BLOOM and BLOSSOM pivotal, Phase 3...

Oct 05, 2014, 19:01 ET

Zonegran® (zonisamide) en monotherapie: publication de l'avis de la Commission de la Transparence

L'avis de la Commission de la Transparence relative à l'extension d'indications de Zonegran® (zonisamide) en monothérapie chez les...

Oct 05, 2014, 19:01 ET

La Comisión de Transparencia Francesa reconoce la eficacia de la monoterapia con Zonegran® (zonisamida)

La Alta Autoridad Sanitaria francesa HAS ha emitido su dictamen de transparecia sobre la monoterapia con Zonegran® (zonisamida) para el...

Oct 01, 2014, 08:30 ET
http://www.multivu.com/players/English/7336651-eisai-inc-epilepsy-foundation-national-survey-shed-light-on-unmet-epilepsy-needs/gallery/image/b06c5598-8fe7-4844-8e73-1d3f03cf95df.HR.png

Results of Eisai Inc. and Epilepsy Foundation National Survey Shed Light on Unmet Needs in Epilepsy Community

Results from a national survey conducted by Eisai Inc., in partnership with the Epilepsy Foundation, found that the vast majority (95%) of epilepsy...

Sep 30, 2014, 10:00 ET

Halaven® (Eribulin) zur lebensverlängernden Behandlung von metastasiertem Brustkrebs in Australien eingeführt

FÜR EU-MEDIEN: NICHT FÜR JOURNALISTEN AUS DER SCHWEIZ/DEN USA  Halaven® (Eribulin) hat die Erstattungszulassung für die...

Sep 30, 2014, 10:00 ET

Lanzamiento en Australia de Halaven® (eribulina), un tratamiento para el cáncer de mama metastásico que prolonga la vida

COMUNICADO DE PRENSA SOLO PARA MEDIOS DE LA UE: NO PARA LOS MEDIOS SUIZOS/ ESTADOUNIDENSES Halaven® (eribulina) ha recibido la...

Sep 30, 2014, 10:00 ET

Halaven® (eribulina), il trattamento che prolunga la vita nel carcinoma mammario metastatico, viene lanciato in Australia

COMUNICATO STAMPA DESTINATO ESCLUSIVAMENTE AI MEDIA DELL'UE: NON DESTINATO AI GIORNALISTI DI SVIZZERA/STATI UNITI  Halaven® (eribulina)...

Sep 27, 2014, 03:15 ET